NASDAQ$RAPP
Rapport Therapeutics Inc · Q4 2025 earnings
Q4 2025 earnings · · Before market open
Briefing
RAPP reported Q4 2025, net loss of $33.8M.
For Q4 2025, RAPP reported a net loss of $33.8M. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.
- Net loss $33.8M.
- RAPP MD&A covers liquidity, credit, and operating priorities.
- RAPP MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
Rapport Therapeutics Inc · Revenue · Quarterly
$0
Forward guidance
Phase 3 FOS program initiation expected Q2 2026; cash into H2 2029.
Tailwinds
- Phase 2a FOS data supportive of Phase 3.
- Tenacia China deal with $20M upfront.
Headwinds
- Q4 net loss $33.8M.
- R&D spend rising with pipeline expansion.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 2 quarterly earnings reports · overlaid with Q4 2025
+2.2%
Avg return
Earnings day
-4.2%
Avg return
5 days after
+4.7%
Avg return
30 days after
50%
1 / 2 earnings
Positive
+7.4%
Q1 2026
Best reaction
-3.0%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.4% | +0.4% | -2.7% | |
| Q4 2025 | -3.0% | -8.8% | +12.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro